Should investors worry about CELU's EPS in 2024?

**Investors should not be overly concerned about CELU's EPS in 2024.** Here's why:

1. **Improvement in Revenue Projections**: Celularity has raised its full-year 2024 expected net sales guidance to $54 million to $60 million, up from $50 million to $56 million. This increase is based on higher expected net sales through October, particularly in advanced biomaterial products.
2. **Strong Product Performance**: Celularity's biomaterial products have generated over $24 million in sales for the first half of 2024. The company's Rebound™ product, introduced recently, has contributed significantly, with expected net sales of more than $9 million.
3. **Earnings Beat Expectations**: In Q3 2022, Celularity's EPS beat expectations, despite a 61% revenue drop and a 90% net income drop compared to Q3 2021. This indicates the company's potential to exceed earnings expectations, which is a positive sign for 2024 EPS projections.
4. **Strategic Partnerships**: Celularity's partnership with AD Ports Group for exclusive distribution in the Middle East is a strategic move that could lead to increased sales and market expansion. Such partnerships can positively impact revenue and, by extension, EPS.
5. **Market Valuation**: Celularity's market cap is $90.6 million, with a P/E ratio of 1.3, significantly lower than the industry average of 28.2. This suggests the stock may be undervalued, which could be attractive to investors looking for potential growth opportunities.

While it's important to monitor Celularity's EPS and other financial metrics, the company's positive revenue trends, strategic initiatives, and market positioning may provide a cushion against potential challenges. Investors should keep a close eye on Celularity's financial performance but may not need to worry excessively about the EPS in 2024, given the company's recent positive developments.